An observational study in Septic Shock and VExUS, sponsored by Antalya Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Antalya Training and Research Hospital · Observational
Among 28 studies in Shock, Septic with a site in Turkey — 5 open to participants now, 6 under way, none of them phase 3. Shock, Septic · Turkey.
Among the 28 studies in Shock, Septic with a site in Turkey, this one is the 14th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2026, is one of 23 observational ones, and was the 23rd registered.
1,078 studies on the registry are indexed under Shock, Septic; 232 are open to participants now.
Browse Shock, Septic studies →5 of the 28 studies in Shock, Septic with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ankara Etlik City Hospital · Sites in Turkey
Ankara City Hospital Bilkent · Sites in Turkey
Melahat Yalcin Solak · Sites in Turkey
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 136 Shock, Septic studies recruiting now, 102 (75%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 100 is close to the median of 108 across 406 observational studies indexed under Shock, Septic.
Median enrollment 67 across the 5 interventional studies, 146 across the 23 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 28 has an industry lead sponsor. The 10 most frequent:
Antalya Training and Research Hospital is the lead sponsor of 104 studies on the registry; 12 are open to participants now.
Antalya Training and Research Hospital has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Septic with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07124741Antalya Training and Research HospitalPrognostic Power of the VEXUS Score in Septic Shock: Effectiveness in Mortality Prediction | 2026-11-30 |
| NCT07774962Istanbul University - CerrahpasaDiscordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock | 2027-06-17 |
Among the 28 studies in Shock, Septic with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the prognostic power of the VEXUS Score in predicting mortality among patients with septic shock in intensive care units.
After the diagnosis of septic shock, patients will be assessed for eligibility. Following informed consent, measurements will be taken within the first 4 hours of shock onset, and treatment (inotropic and vasopressor doses, fluid challenge, corticosteroids) will be recorded. A second measurement will occur between 12 and 24 hours, and a third at 72 hours. All treatment and care protocols will be managed according to routine unit protocols.
Data will be systematically collected at three time points (0-4 hours, 12-24 hours, and 72 hours). These will include hemodynamic parameters, laboratory tests (including infection markers), need for renal replacement therapy, mechanical ventilation requirement and duration, cumulative dose and duration of vasopressor use, ICU stay, and survival status.
VEXUS Score Grading
The VEXUS score will be graded as follows:
Data will be analyzed using SPSS version 23.0, with normality assessed through visual and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). Continuous variables will be compared using t-tests or Mann-Whitney U tests, and categorical variables using Chi-square tests. ROC analysis will be used to assess the predictive value of VEXUS for mortality.
Adult patients admitted to the intensive care unit with a diagnosis of septic shock according to Sepsis-3 criteria. Patients will be enrolled consecutively from the intensive care unit of a tertiary care university hospital. Informed consent will be obtained from all patients or their legal representatives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients diagnosed with septic shock in the ıntensive care unit will undergo serial ultrasonographic evaluations to calculate the VEXUS Score at 0-4 hours, 12-24 hours, and 72 hours. These scores will be analyzed in relation to 28-day mortality. No treatment decisions will be made based on the VEXUS results.
Diagnostic Test: Serial VEXUS Ultrasound Evaluation
Ultrasound assessments will be performed by an experienced anesthesiologist at three time points (0-4 hours, 12-24 hours, and 72 hours)to determine the degree of venous congestion using the VEXUS Score. No treatment changes will be made based on the VEXUS findings. The scores will solely be used for prognostic correlation with mortality outcomes.
28-day intensive care unit mortality in relation to VEXUS score
Investigation of the relationship between VEXUS Score and 28-day mortality in patients diagnosed with septic shock in the intensive care unit.
Time frame: Up to 28 days following intensive care unit admission.
Need for mechanical ventilation in relation to VEXUS score
Evaluation of the association between initial VEXUS score and the requirement for mechanical ventilation in patients
Time frame: Within the first 72 hours of intensive care unit admission.
Duration of mechanical ventilation in relation to VEXUS score.
Assessment of the correlation between VEXUS scores and the total duration of mechanical ventilation in intensive care unit patients with septic shock.
Time frame: From intensive care unit patients admission until extubation, up to 28 days.
Length of intensive care unit stay in relation to VEXUS score
Investigation of the association between VEXUS score pregression and total length of intensive care unit stay in patients with septic shock.
Time frame: From intensive care unit admission until intensive care unit discharge, up to 28 days.
Vasopressor dose and duration in relation to VEXUS score.
Assessment of the relationship between serial VEXUS scores and the cumulative dose and duration of vasopressor therapy during the first 72 hours in patients diagnosed with septic shock.
Time frame: First 72 hours after intensive care unit admission
Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.
Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 8 months is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Antalya Training and Research Hospital →